NeoGenomics launches AML Express NGS assay
Oct. 9, 2024—NeoGenomics has launched its AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
CAP files amicus brief in LDT lawsuits
Oct. 8, 2024—The College of American Pathologists on Oct. 7 filed an amicus brief in support of the plaintiffs in the consolidated cases American Clinical Laboratory Association, et al., v. U.S. Food and Drug Administration, et al., and Association for Molecular Pathology, et al., v. U.S. Food and Drug Administration, et al.
Qiagen launches QIAcuityDx dPCR system for oncology testing
Oct. 7, 2024—Qiagen announced the launch of the QIAcuityDx digital PCR system, an IVD medical device that integrates partitioning, thermocycling, and imaging into a streamlined five-plex workflow in a single instrument.
Proscia launches Concentriq Embeddings, AI Toolkit
Oct. 2, 2024—Proscia announced the launch of Concentriq Embeddings and Proscia AI Toolkit.
QIAstat-Dx instruments, assays get IVDR certification
Oct. 1, 2024—Qiagen announced that its QIAstat-Dx syndromic testing systems and associated assays have received CE marking under the European Union in vitro diagnostic medical devices regulation.
Trial shows MeMed BV reduces use of unnecessary antibiotics
Sept. 30, 2024—MeMed announced the completion of its first randomized controlled trial to evaluate the MeMed BV test in the United States.
Unity Next Peer QC offered with Sysmex hemostasis systems
Sept. 23, 2024—Bio-Rad Laboratories has announced a partnership with Sysmex America in Bio-Rad’s Unity Next Peer QC software is now available with Sysmex CA-Series and CS-Series hemostasis systems for the United States.
Kisqali OK’d in people with HR+/HER2- early breast cancer
Sept. 20, 2024—Novartis announced FDA approval of Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of people with HR+/HER2- stage II and III early breast cancer at high risk of recurrence, including those with node-negative disease.
Pathology Visions 2024—Decision Digital
Sept. 18, 2024—The Digital Pathology Association (DPA) invites you to attend this year’s annual meeting, taking place Nov. 3–5 in Orlando, Fla.
Qiagen calls for increased TB testing in the U.S.
Sept. 17, 2024—Qiagen is calling for a sharper focus on testing strategies to stop new cases of tuberculosis from further increasing and spreading in the United States.